Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer

Research output: Contribution to journalArticleOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)617-619
Number of pages3
JournalCurrent Opinion in Urology
Volume30
Issue number4
DOIs
Publication statusPublished - 1 Jul 2020

Cite this